Real‐world effectiveness and safety of insulin glargine 300 U/ml in insulin‐naïve people with type 2 diabetes in the Latin America region: A subgroup analysis of the A Toujeo Observational Study (ATOS)
Authors' conclusion
In a real-world setting in the Latin America region, the initiation of Gla-300 in people with T2D uncontrolled on OADs resulted in improved glycaemic control with a low incidence of hypoglycaemia and no change in body weight.
Study context
- Population
- Insulin-naïve adults (≥18 years) with T2D uncontrolled (HbA1c >7% and ≤11%) on ≥1 oral antidiabetic drug (OAD), Mexico, Colombia and Peru (Latin America region); mean age 56.0 ± 11.6 years, diabetes duration 9.7 ± 6.6 years, 65.9% on ≥2 OADsLatin America subgroup
- Participants
- 314 adults
- Primary endpoint
- Percentage of participants achieving their predefined individualized HbA1c goal
- Follow-up
- Month 6
Methodological detailsmulticentre, 12-month, real-world
- Multicentre
- 12-month
- Real-world
Primary result
As reported in the abstract
Individualized HbA1c target achieved
Participants achieving individualized HbA1c target
25.8%
95% CI 20.3–31.9
Secondary outcomes
Individualized HbA1c target achieved · month 12
- Participants achieving individualized HbA1c target
- 35.3% (95% CI 28.5-42.5)
HbA1c, fasting plasma glucose (FPG) and fasting self-monitored blood glucose (SMBG)
- Gla-300 treatment improved glycaemic control with meaningful reductions in mean HbA1c, FPG and fasting SMBG
Body weight
- Body weight remained stable
Safety
- Incidence of hypoglycaemia was low
- Body weight remained stable
Original publication
Real‐world effectiveness and safety of insulin glargine 300 U/ml in insulin‐naïve people with type 2 diabetes in the Latin America region: A subgroup analysis of the ATOS. Diabetes Obes Metab. Published 9 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →